Neuroprotective maraviroc monotherapy in simian immunodeficiency virus-infected macaques: reduced replicating and latent SIV in the brain

Objective:HIV-associated neurocognitive deficits remain a challenge despite suppressive combined antiretroviral therapy. Given the association between HIV-induced central nervous system (CNS) disease and replication of HIV in immune-activated macrophages, CCR5 antagonists may attenuate CNS disease by modulating inflammatory signaling and by limiting viral replication. Design:To establish whether initiating CCR5 inhibition during early infection altered CNS disease progression, outcomes were compared between simian immunodeficiency virus (SIV)-infected macaques treated with maraviroc (MVC) versus untreated SIV-infected macaques. Methods:Six SIV-infected rhesus macaques were treated with MVC monotherapy for 5 months beginning 24 days postinoculation; 22 SIV-infected animals served as untreated controls. SIV RNA levels in plasma, cerobrospinal fluid, and brain, and CNS expression of TNF&agr; and CCL2 were measured by qRT-PCR. Immunostaining for CD68 and amyloid precursor protein in the brain was measured by image analysis. Plasma sCD163 was measured by ELISA. Results:SIV RNA and proviral DNA levels in brain were markedly lower with MVC treatment, demonstrating CCR5 inhibition reduces CNS replication of SIV and may reduce the CNS latent viral reservoir. MVC treatment also lowered monocyte and macrophage activation, represented by CNS CD68 immunostaining and plasma sCD163 levels, and reduced both TNF&agr; and CCL2 RNA expression in brain. Treatment also reduced axonal amyloid precursor protein immunostaining to levels present in uninfected animals, consistent with neuroprotection. Conclusion:CCR5 inhibitors may prevent neurologic disorders in HIV-infected individuals by reducing inflammation and by limiting viral replication in the brain. Furthermore, CCR5 inhibitors may reduce the latent viral reservoir in the CNS. Adding CCR5 inhibitors to combined antiretroviral regimens may offer multiple neuroprotective benefits.

[1]  M. Lederman,et al.  The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. , 2013, Blood.

[2]  M. Peluso,et al.  Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. , 2013, The Journal of infectious diseases.

[3]  R. Ellis,et al.  Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection , 2013, AIDS.

[4]  A. Della Corte,et al.  A Highly Intensified ART Regimen Induces Long-Term Viral Suppression and Restriction of the Viral Reservoir in a Simian AIDS Model , 2012, PLoS pathogens.

[5]  D. Kass,et al.  Diastolic dysfunction is associated with myocardial viral load in simian immunodeficiency virus-infected macaques , 2012, AIDS.

[6]  K. Robertson,et al.  Antiretroviral neurotoxicity , 2012, Journal of NeuroVirology.

[7]  V. Vullo,et al.  In vitro effect of anti‐human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells , 2011, Clinical and experimental immunology.

[8]  J. Clements,et al.  Replication-Competent Simian Immunodeficiency Virus (SIV) Gag Escape Mutations Archived in Latent Reservoirs during Antiretroviral Treatment of SIV-Infected Macaques , 2011, Journal of Virology.

[9]  Michael J. Taylor,et al.  Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort , 2011, AIDS.

[10]  J. Clements,et al.  Central nervous system correlates of behavioral deficits following simian immunodeficiency virus infection , 2003, Journal of NeuroVirology.

[11]  D. Podzamczer,et al.  Maraviroc Concentrations in Cerebrospinal Fluid in HIV-Infected Patients , 2010, Journal of acquired immune deficiency syndromes.

[12]  D. Fuchs,et al.  Treatment Intensification Has no Effect on the HIV-1 Central Nervous System Infection in Patients on Suppressive Antiretroviral Therapy , 2010, Journal of acquired immune deficiency syndromes.

[13]  M. Gill,et al.  Neurologic disease burden in treated HIV/AIDS predicts survival , 2010, Neurology.

[14]  V. Calvez,et al.  Maraviroc-containing regimen suppresses HIV replication in the cerebrospinal fluid of patients with neurological symptoms , 2010, AIDS (London).

[15]  J. Clements,et al.  Simian immunodeficiency virus-infected macaques treated with highly active antiretroviral therapy have reduced central nervous system viral replication and inflammation but persistence of viral DNA. , 2010, The Journal of infectious diseases.

[16]  J. McArthur,et al.  Human immunodeficiency virus‐associated neurocognitive disorders: Mind the gap , 2010, Annals of neurology.

[17]  J. Clements,et al.  Coordinated Regulation of SIV Replication and Immune Responses in the CNS , 2009, PloS one.

[18]  E. Wright.  Neurological disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation , 2009, Current opinion in HIV and AIDS.

[19]  J. Inoue,et al.  Selective Transmission of R5 HIV-1 over X4 HIV-1 at the Dendritic Cell–T Cell Infectious Synapse Is Determined by the T Cell Activation State , 2009, PLoS pathogens.

[20]  C. Fernandez,et al.  Natural Host Genetic Resistance to Lentiviral CNS Disease: A Neuroprotective MHC Class I Allele in SIV-Infected Macaques , 2008, PloS one.

[21]  M. Cherner,et al.  Co-factors in HIV neurobehavioural disturbances: Substance abuse, hepatitis C and aging , 2008, International review of psychiatry.

[22]  Dianne Langford,et al.  HIV and antiretroviral therapy in the brain: neuronal injury and repair , 2008, Nature Reviews Neuroscience.

[23]  J. Becker,et al.  Updated research nosology for HIV-associated neurocognitive disorders , 2007, Neurology.

[24]  Justin C McArthur,et al.  The prevalence and incidence of neurocognitive impairment in the HAART era , 2007, AIDS.

[25]  Thomas Unger,et al.  Quantitative real-time RT-PCR data analysis: current concepts and the novel “gene expression’s CT difference” formula , 2006, Journal of Molecular Medicine.

[26]  J. Clements,et al.  The central nervous system as a reservoir for simian immunodeficiency virus (SIV): steady-state levels of SIV DNA in brain from acute through asymptomatic infection. , 2002, The Journal of infectious diseases.

[27]  V. Perry,et al.  Accumulation of β‐Amyloid Precursor Protein in Axons Correlates with CNS Expression of SIV gp41 , 2002 .

[28]  J. Clements,et al.  Increased macrophage chemoattractant protein-1 in cerebrospinal fluid precedes and predicts simian immunodeficiency virus encephalitis. , 2001, The Journal of infectious diseases.

[29]  J. Clements,et al.  High Viral Load in the Cerebrospinal Fluid and Brain Correlates with Severity of Simian Immunodeficiency Virus Encephalitis , 1999, Journal of Virology.

[30]  J. Clements,et al.  Pathogenesis of SIV encephalitis. Selection and replication of neurovirulent SIV. , 1997, The American journal of pathology.